Compare Adaptive Biotechnologies Corp (ADPT) vs ASML Holding NV (ASML) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ASML Holding NV — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.05B), while ASML Holding NV trades at $1,805.22 (market cap $671.92B). The key difference: ASML Holding NV is far larger — about 165.9× Adaptive Biotechnologies Corp's market cap, and ASML Holding NV pays a 0.52% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ASML | |
|---|---|---|
Market Cap | $4.05B | $671.92B |
Sector | Health | Technology |
52-Week High | $25.45 | $1.99K |
52-Week Low | $12.15 | $721.31 |
Enterprise Value | $4.12B | $665.45B |
Dividend Yield | — | 0.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
ASML trades at $1,740.99, up 2.15% today, with a bullish technical signal and strong support near $1,721. The stock shows robust fundamentals with 2025 revenue of $32.67B and net income of $9.61B, though high valuation ratios like a P/E of 59.29 indicate premium pricing. Recent earnings beat expectations in Q1 and Q2 2026, and analyst consensus is bullish with a $2,390 price target.
Outlook remains positive driven by AI demand for semiconductor equipment, but risks include geopolitical tensions with China and high valuation sensitivity. Institutional sentiment is strong with 56.82% buy ratings, though competition and export curbs pose challenges to growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →
